180 related articles for article (PubMed ID: 37029223)
1. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2023 Jun; 58(6):575-585. PubMed ID: 37029223
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis.
Terashima T; Yamashita T; Sakai A; Ohta H; Hinoue Y; Toya D; Kawai H; Yonejima M; Urabe T; Noda Y; Mizukoshi E; Kaneko S
Jpn J Clin Oncol; 2018 Nov; 48(11):966-973. PubMed ID: 30256958
[TBL] [Abstract][Full Text] [Related]
3. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database.
Sakakida T; Ishikawa T; Doi T; Morita R; Kataoka S; Miyake H; Yamaguchi K; Moriguchi M; Sogame Y; Yasuda H; Iwasaku M; Konishi H; Takayama K; Itoh Y
J Gastroenterol; 2024 Feb; 59(2):145-156. PubMed ID: 38006445
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of chemotherapy for patients with metastatic or recurrent pancreatic adenosquamous carcinoma: A multicenter retrospective analysis.
Yoshida Y; Kobayashi S; Ueno M; Morizane C; Tsuji K; Maruki Y; Mori K; Watanabe K; Ohba A; Furuta M; Todaka A; Tsujimoto A; Ozaka M; Okano N; Yane K; Umemoto K; Kawamoto Y; Terashima T; Tsumura H; Doi K; Shioji K; Asagi A; Kojima Y; Suzuki E; Toshiyama R; Furukawa M; Naganuma A; Suzuki R; Miwa H; Ikeda M; Furuse J
Pancreatology; 2022 Dec; 22(8):1159-1166. PubMed ID: 36150984
[TBL] [Abstract][Full Text] [Related]
5. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and surgical outcomes of resectable acinar cell carcinoma of the pancreas-propensity score matching analysis with pancreatic ductal adenocarcinoma.
Chen H; Xu Z; Shen Z; Weng Y; Wang W; Ying X; Wang X; Deng X; Shen B
Eur J Surg Oncol; 2022 May; 48(5):1062-1067. PubMed ID: 34887166
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract][Full Text] [Related]
8. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
9. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma.
Golan T; O'Kane GM; Denroche RE; Raitses-Gurevich M; Grant RC; Holter S; Wang Y; Zhang A; Jang GH; Stossel C; Atias D; Halperin S; Berger R; Glick Y; Park JP; Cuggia A; Williamson L; Wong HL; Schaeffer DF; Renouf DJ; Borgida A; Dodd A; Wilson JM; Fischer SE; Notta F; Knox JJ; Zogopoulos G; Gallinger S
Gastroenterology; 2021 May; 160(6):2119-2132.e9. PubMed ID: 33524400
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer.
Ay S; Atcı MM; Arıkan R; Dülgar Ö; Özyükseler DT; Paksoy N; Doğan İ; Öztosun B; Taştekin D; Öven BB; Gümüş M
J Chemother; 2022 Nov; 34(7):465-471. PubMed ID: 35037592
[TBL] [Abstract][Full Text] [Related]
11. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
[TBL] [Abstract][Full Text] [Related]
12. First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Gulhati P; Prakash L; Katz MHG; Wang X; Javle M; Shroff R; Fogelman D; Lee JE; Tzeng CD; Lee JH; Weston B; Tamm E; Bhosale P; Koay EJ; Maitra A; Wang H; Wolff RA; Varadhachary GR
Ann Surg Oncol; 2019 Feb; 26(2):619-627. PubMed ID: 30324485
[TBL] [Abstract][Full Text] [Related]
13. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
[TBL] [Abstract][Full Text] [Related]
15. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic acinar cell carcinoma is associated with
Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
[TBL] [Abstract][Full Text] [Related]
17. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.
Florou V; Elliott A; Bailey MH; Stone D; Affolter K; Soares HP; Nevala-Plagemann C; Scaife C; Walker P; Korn WM; Lou E; Shroff RT; Hosein PJ; Garrido-Laguna I
Clin Cancer Res; 2023 Sep; 29(17):3408-3417. PubMed ID: 37266563
[TBL] [Abstract][Full Text] [Related]
18. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
19. A multigene circulating biomarker to predict the lack of FOLFIRINOX response after a single cycle in patients with pancreatic ductal adenocarcinoma.
van Eijck CWF; de Koning W; van der Sijde F; Moskie M; Groot Koerkamp B; Homs MYV; van der Burg SH; van Eijck CHJ; Mustafa DAM
Eur J Cancer; 2023 Mar; 181():119-134. PubMed ID: 36652890
[TBL] [Abstract][Full Text] [Related]
20. Regulation of pH by Carbonic Anhydrase 9 Mediates Survival of Pancreatic Cancer Cells With Activated KRAS in Response to Hypoxia.
McDonald PC; Chafe SC; Brown WS; Saberi S; Swayampakula M; Venkateswaran G; Nemirovsky O; Gillespie JA; Karasinska JM; Kalloger SE; Supuran CT; Schaeffer DF; Bashashati A; Shah SP; Topham JT; Yapp DT; Li J; Renouf DJ; Stanger BZ; Dedhar S
Gastroenterology; 2019 Sep; 157(3):823-837. PubMed ID: 31078621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
